+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiovascular Therapeutics Market by Therapeutic Type (Medical Devices, Pharmaceuticals), Age Group (Adult, Geriatric, Pediatric), Disease Indication, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Cardiovascular Therapeutics Market by Therapeutic Type (Medical Devices, Pharmaceuticals), Age Group (Adult, Geriatric, Pediatric), Disease Indication, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Cardiovascular Therapeutics Market by Therapeutic Type (Medical Devices, Pharmaceuticals), Age Group (Adult, Geriatric, Pediatric), Disease Indication, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010725
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cardiovascular Therapeutics Market is undergoing accelerated transformation, shaped by demographic trends, emerging technologies, and evolving care models. Senior executives navigating this space face a rapidly evolving landscape that demands precise strategic alignment and informed investment decisions.

Market Snapshot: Cardiovascular Therapeutics Market Growth Insights

The cardiovascular therapeutics market advanced from USD 211.18 billion in 2024 to USD 224.67 billion in 2025, reflecting ongoing momentum. With a projected CAGR of 6.49%, the sector is expected to reach USD 308.03 billion by 2030, underpinned by persistent innovation, expanded clinical need, and the adoption of digital and precision-based healthcare.

Scope & Segmentation

  • Therapeutic Type: Medical devices (including implantable solutions and interventional platforms), pharmaceuticals such as antiarrhythmics, antihyperlipidemics, antihypertensives, antiplatelets, anticoagulants, and vasodilators.
  • Patient Demographics: Adult, geriatric, and pediatric populations with distinct clinical considerations and compliance factors.
  • Disease Indications: Arrhythmia, congenital heart disease, coronary artery disease, heart failure, hyperlipidemia, hypertension, thromboembolic disorders, and valvular heart disease.
  • End Users: Ambulatory surgical centers, clinics, home care, and hospitals, each with unique procurement cycles and care protocols.
  • Distribution Channels: Offline and online platforms influencing patient and provider engagement.
  • Regions: Americas (including the United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (varied reimbursement and regulatory models across key countries); and Asia-Pacific (driven by expanding investment, emerging partnerships, and digital integration).
  • Leading Players: Abbott Laboratories, Alnylam Pharmaceuticals, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, BridgeBio Pharma, Bristol‑Myers Squibb, Cardurion Therapeutics, Cleerly, CRISPR Therapeutics, CVRx, Cytokinetics, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, F. Hoffmann-La Roche, GE HealthCare Technologies, Ionis Pharmaceuticals, Johnson & Johnson, Medtronic, Merck, NewAmsterdam Pharma, Novartis, Pfizer, Sanofi, Silence Therapeutics, Tenaya Therapeutics, Verve Therapeutics, and others.

Key Takeaways for Senior Decision-Makers

  • The market’s evolution is driven by technological advances such as AI-enabled diagnostics, remote monitoring solutions, and minimally invasive devices, changing how diseases are detected and managed.
  • Adoption of precision medicine, supported by genomic profiling and biomarker analytics, optimizes therapeutic outcomes and enables risk stratification for targeted patient subsets.
  • Healthcare delivery models are shifting toward value-based care, prompting stakeholders to emphasize long-term outcomes, cost containment, and sustainable access.
  • Emerging digital platforms and wearables are empowering both practitioners and patients, improving adherence and reducing readmission risks across diverse care settings.
  • Industry leaders are blending organic R&D with strategic partnerships spanning device developers, pharmaceutical firms, and tech innovators, enabling the creation of integrated digital ecosystems.

Tariff Impact: Shaping Supply Chains and Manufacturing Choices

  • Recent tariff adjustments in the United States are compelling manufacturers to reassess sourcing and production strategies, with a shift toward domestic alternatives and supply chain resilience.
  • Joint ventures between local and global players have become crucial for overcoming tariff barriers and maintaining market competitiveness.
  • Healthcare providers are responding to cost pressures by intensifying formulary management and seeking evidence-backed value guarantees from suppliers.

Methodology & Data Sources

This report utilizes primary research via interviews with clinicians, procurement leaders, and payer representatives, supplemented by secondary analysis of clinical literature, regulatory filings, and company disclosures. Findings were validated through focus group feedback and independent data audits to ensure reliability and actionable insights.

Why This Report Matters

  • Enables senior executives to benchmark strategic initiatives against market trends and competitive positioning.
  • Informs investment planning by clarifying regional priorities, technology adoption pathways, and regulatory considerations.
  • Delivers actionable insights for aligning product portfolios with evolving clinical practices and payer requirements.

Conclusion

Decision-makers in the cardiovascular therapeutics sector gain a robust foundation for planning and execution. The report offers clarity on market forces, technology trends, and stakeholder dynamics to drive resilient growth and improved clinical outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in use of PCSK9 inhibitors following expanded clinical indications for hypercholesterolemia management
5.2. Integration of digital health tools and remote monitoring in heart failure management protocols boosting patient outcomes
5.3. Emergence of RNA-based therapies targeting atrial fibrillation at genetic level transforming treatment paradigms
5.4. Utilization of AI-driven predictive analytics for early detection of cardiovascular disease risk factors
5.5. Rising adoption of minimally invasive transcatheter valve replacement procedures in elderly patient populations
5.6. Development of nanoparticle-based drug delivery systems improving targeted therapy for atherosclerosis
5.7. Growth of telecardiology services and virtual cardiac rehabilitation programs expanding patient access to care
5.8. Investment surge in microfluidic organ-on-chip models accelerating preclinical cardiovascular drug testing
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cardiovascular Therapeutics Market, by Therapeutic Type
8.1. Introduction
8.2. Medical Devices
8.2.1. Implantable Devices
8.2.1.1. Cardiac Resynchronization Therapy Devices
8.2.1.2. Heart Valves
8.2.1.3. Implantable Cardioverter-Defibrillators
8.2.1.4. Left Ventricular Assist Devices
8.2.1.5. Pacemakers
8.2.2. Interventional Devices
8.2.2.1. Atherectomy Devices
8.2.2.2. Balloon Catheters
8.2.2.3. Guidewires & Microcatheters
8.2.2.4. Stents
8.2.2.5. Thrombectomy Devices
8.2.3. Monitoring Devices
8.2.3.1. ECG Devices
8.2.3.2. Holter Monitors
8.2.4. Surgical Equipment
8.3. Pharmaceuticals
8.3.1. Antiarrhythmic Drugs
8.3.1.1. Class I
8.3.1.2. Class II
8.3.1.3. Class III
8.3.1.4. Class IV
8.3.2. Antihyperlipidemic Drugs
8.3.2.1. Bile Acid Sequestrants
8.3.2.1.1. Cholestyramine
8.3.2.1.2. Colesevelam
8.3.2.1.3. Colestipol
8.3.2.2. Fibrates
8.3.2.3. Statins
8.3.2.3.1. Atorvastatin
8.3.2.3.2. Rosuvastatin
8.3.2.3.3. Simvastatin
8.3.3. Antihypertensive Drugs
8.3.3.1. ACE Inhibitors
8.3.3.1.1. Captopril
8.3.3.1.2. Lisinopril
8.3.3.1.3. Ramipril
8.3.3.2. Angiotensin II Receptor Blockers
8.3.3.2.1. Irbesartan
8.3.3.2.2. losartan
8.3.3.2.3. Valsartan
8.3.3.3. Beta-blockers
8.3.3.3.1. Atenolol
8.3.3.3.2. Metoprolol
8.3.3.3.3. Propranolol
8.3.3.4. Calcium Channel Blockers
8.3.4. Antiplatelet & Anticoagulant Drugs
8.3.4.1. Aspirin
8.3.4.2. Clopidogrel
8.3.4.3. Warfarin
8.3.5. Vasodilators
9. Cardiovascular Therapeutics Market, by Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Cardiovascular Therapeutics Market, by Disease Indication
10.1. Introduction
10.2. Arrhythmia
10.3. Congenital Heart Disease
10.4. Coronary Artery Disease
10.5. Heart Failure
10.6. Hyperlipidemia
10.7. Hypertension
10.8. Thromboembolic Disorders
10.9. Valvular Heart Diseases
11. Cardiovascular Therapeutics Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Home Care
11.5. Hospitals
12. Cardiovascular Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Americas Cardiovascular Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cardiovascular Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cardiovascular Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Alnylam Pharmaceuticals, Inc.
16.3.3. Amgen Inc.
16.3.4. AstraZeneca PLC
16.3.5. Bayer AG
16.3.6. Boehringer Ingelheim GmbH
16.3.7. Boston Scientific Corporation
16.3.8. BridgeBio Pharma, Inc.
16.3.9. Bristol-Myers Squibb Company
16.3.10. Cardurion Therapeutics, Inc.
16.3.11. Cleerly, Inc.
16.3.12. CRISPR Therapeutics AG
16.3.13. CVRx, Inc.
16.3.14. Cytokinetics, Inc.
16.3.15. Daiichi Sankyo Company, Limited
16.3.16. Eli Lilly and Company
16.3.17. Esperion Therapeutics, Inc.
16.3.18. F. Hoffmann-La Roche Ltd.
16.3.19. GE HealthCare Technologies Inc.
16.3.20. Ionis Pharmaceuticals, Inc.
16.3.21. Johnson & Johnson Services, Inc.
16.3.22. Medtronic plc
16.3.23. Merck & Co., Inc.
16.3.24. NewAmsterdam Pharma B.V.
16.3.25. Novartis AG
16.3.26. Pfizer Inc.
16.3.27. Sanofi S.A.
16.3.28. Silence Therapeutics PLC
16.3.29. Tenaya Therapeutics, Inc.
16.3.30. Verve Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CARDIOVASCULAR THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CARDIOVASCULAR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CARDIOVASCULAR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CARDIOVASCULAR THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. CARDIOVASCULAR THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. CARDIOVASCULAR THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. CARDIOVASCULAR THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CARDIOVASCULAR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART VALVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PACEMAKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GUIDEWIRES & MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GUIDEWIRES & MICROCATHETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ECG DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ECG DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOLTER MONITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOLTER MONITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY SURGICAL EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY SURGICAL EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS I, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS I, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS II, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS II, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS III, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS III, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLASS IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COLESTIPOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COLESTIPOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY FIBRATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CAPTOPRIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CAPTOPRIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LISINOPRIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RAMIPRIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY RAMIPRIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IRBESARTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IRBESARTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY LOSARTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY VALSARTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY VALSARTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ATENOLOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY METOPROLOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PROPRANOLOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CONGENITAL HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CONGENITAL HEART DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY VALVULAR HEART DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY VALVULAR HEART DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 175. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 177. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 179. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 183. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 265. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
TABLE 266. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2030 (USD MILLION)
TABLE 267. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2024 (USD MILLION)
TABLE 268. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2025-2030 (USD MILLION)
TABLE 269. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2024 (USD MILLION)
TABLE 270. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, 2025-2030 (USD MILLION)
TABLE 271. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2018-2024 (USD MILLION)
TABLE 272. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY INTERVENTIONAL DEVICES, 2025-2030 (USD MILLION)
TABLE 273. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
TABLE 274. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, 2025-2030 (USD MILLION)
TABLE 275. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 276. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 277. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 278. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 279. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2018-2024 (USD MILLION)
TABLE 280. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERLIPIDEMIC DRUGS, 2025-2030 (USD MILLION)
TABLE 281. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 282. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 283. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 284. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 285. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2018-2024 (USD MILLION)
TABLE 286. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, 2025-2030 (USD MILLION)
TABLE 287. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2018-2024 (USD MILLION)
TABLE 290. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, 2025-2030 (USD MILLION)
TABLE 291. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2018-2024 (USD MILLION)
TABLE 292. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, 2025-2030 (USD MILLION)
TABLE 293. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2018-2024 (USD MILLION)
TABLE 294. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY ANTIPLATELET & ANTICOAGULANT DRUGS, 2025-2030 (USD MILLION)
TABLE 295. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 296. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 297. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 298. CANADA CARDIOVASCULAR THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Cardiovascular Therapeutics market report include:
  • Abbott Laboratories
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • BridgeBio Pharma, Inc.
  • Bristol‑Myers Squibb Company
  • Cardurion Therapeutics, Inc.
  • Cleerly, Inc.
  • CRISPR Therapeutics AG
  • CVRx, Inc.
  • Cytokinetics, Inc.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • NewAmsterdam Pharma B.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Silence Therapeutics PLC
  • Tenaya Therapeutics, Inc.
  • Verve Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 224.67 Billion
Forecasted Market Value ( USD ) by 2030 $ 308.03 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Cardiovascular Clinical Trials - Global Strategic Business Report - Product Image

Cardiovascular Clinical Trials - Global Strategic Business Report

  • Report
  • 393 Pages
  • Global
From
Cardiovascular Drugs Market by Product Type (Anti-Arrhythmics, Anti-Hypertensives, Anticoagulants), Dosage Form (Injectable, Oral, Topical), Therapy Type, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Cardiovascular Drugs Market by Product Type (Anti-Arrhythmics, Anti-Hypertensives, Anticoagulants), Dosage Form (Injectable, Oral, Topical), Therapy Type, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Calcium Channel Blockers Market by Type (Dihydropyridine, Non-Dhp), Indication (Angina, Arrhythmia, Hypertension), Distribution Channel, Route, End User - Global Forecast 2025-2030 - Product Image

Calcium Channel Blockers Market by Type (Dihydropyridine, Non-Dhp), Indication (Angina, Arrhythmia, Hypertension), Distribution Channel, Route, End User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Cardiovascular Drugs - Global Strategic Business Report - Product Image

Cardiovascular Drugs - Global Strategic Business Report

  • Report
  • 413 Pages
  • Global
From
Angina Pectoris Drugs - Global Strategic Business Report - Product Image

Angina Pectoris Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From

About the Cardiovascular Drugs Market

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.